Download PDF
Hamostaseologie
DOI: 10.1055/a-2337-4025
Review Article

Antithrombotic Therapy in Cancer Patients with Cardiovascular Diseases: Daily Practice Recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society for Thrombosis and Hemostasis Research (GTH e.V.)

Stefani Parmentier
1   Tumorzentrum, St. Claraspital Tumorzentrum, St. Claraspital, Basel, Basel-Stadt, Switzerland
,
Steffen Koschmieder
2   Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany
,
Larissa Henze
3   Department of Medicine, Clinic III - Hematology, Oncology, Palliative Medicine, Rostock University Medical Center, Rostock, Germany
4   Department of Internal Medicine II, Hematology, Oncology and Palliative Medicine, Asklepios Hospital Harz, Goslar, Germany
,
Martin Griesshammer
5   University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
,
Axel Matzdorff
6   Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany
,
Tamam Bakchoul
7   Department of Transfusion Medicine, Medical Faculty of Tübingen, University of Tübingen, Tübingen, Germany
,
Florian Langer
8   Center for Oncology, University Cancer Center Hamburg (UCCH), II Medical Clinic and Polyclinic, University Medical Center Eppendorf, Hamburg, Germany
,
Rosa Sonja Alesci
9   IMD Blood Coagulation Center, Hochtaunus/Frankfurt, Bad Homburg, Germany
,
Daniel Duerschmied
10   Department of Cardiology, Hemostaseology, Angiology and Medical Intensive Care, Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
,
Goetz Thomalla
11   Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Hanno Riess
12   Division of Hematology, Oncology and Tumorimmunology, Department of Medical, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Active cancer by itself but also chemotherapy is associated with an increased risk of cardiovascular disease (CVD) and especially coronary artery disease (CAD) and atrial fibrillation (AF). The frequency of CVD, CAD, and AF varies depending on comorbidities (particularly in older patients), cancer type, and stage, as well as the anticancer therapeutic being taken. Many reports exist for anticancer drugs being associated with CVD, CAD, and AF, but robust data are often lacking. Because of this, each patient needs an individual structured approach concerning thromboembolic and bleeding risk, drug–drug interactions, as well as patient preferences to evaluate the need for anticoagulation therapy and targeting optimal symptom control. Interruption of specific cancer therapy should be avoided to reduce the potential risk of cancer progression. Nevertheless, additional factors like thrombocytopenia and anticoagulation in the elderly and frail patient with cancer cause additional challenges which need to be addressed in daily clinical management. Therefore, the aim of these recommendations is to summarize the available scientific data on antithrombotic therapy (both antiplatelet and anticoagulant therapy) in cancer patients with CVD and in cases of missing data providing guidance for optimal careful decision-making in daily routine.

Keywords

cancer - atrial fibrillation - antithrombotic therapy - coronary artery disease - platelet disorders

Authors' Contributions

S.P., H.R.: conceived and planned the project, wrote parts of the manuscript, completed and revised the whole manuscript; S.K., L.H., M.G., A.M., T.B., F.L., R.S.A.: wrote paragraphs of the manuscript and revised the manuscript; D.D., G.T.: revised the manuscript and added relevant aspects to the manuscript. All authors have read and agreed to the published version of the manuscript.




Publication History

Received: 01 April 2024

Accepted: 30 May 2024

Article published online:
15 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization. WHO Fact Sheet on Cardiovascular Diseases. Accessed June 7, 2024 at: https://www.who.int/news-room/fact-sheets/detal/cardiovascular-diseases-(cvds 2021
    PubMedGoogle Scholar
  • 2 World Health Organization. WHO Leading causes of death globally. Accessed June 7, 2024 at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death 2021
    PubMedGoogle Scholar
  • 3 Virani SS, Alonso A, Aparicio HJ. et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation 2021; 143 (08) e254-e743
    CrossrefPubMedGoogle Scholar
  • 4 Carrillo-Estrada M, Bobrowski D, Carrasco R. et al. Coronary artery disease in patients with cancer: challenges and opportunities for improvement. Curr Opin Cardiol 2021; 36 (05) 597-608
    CrossrefPubMedGoogle Scholar
  • 5 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
    CrossrefPubMedGoogle Scholar
  • 6 Kobo O, Khattak S, Lopez-Mattei J. et al. Trends in cardiovascular mortality of cancer patients in the US over two decades 1999-2019. Int J Clin Pract 2021; 75 (11) e14841
    CrossrefPubMedGoogle Scholar
  • 7 Pons-Riverola A, Morillas H, Berdejo J. et al. Developing cardio-oncology programs in the new era: beyond ventricular dysfunction due to cancer treatments. Cancers (Basel) 2023; 15 (24) 5885
    CrossrefPubMedGoogle Scholar
  • 8 Parent S, Pituskin E, Paterson DI. The cardio-oncology program: a multidisciplinary approach to the care of cancer patients with cardiovascular disease. Can J Cardiol 2016; 32 (07) 847-851
    CrossrefPubMedGoogle Scholar
  • 9 Melloni C, Shrader P, Carver J. et al; ORBIT-AF Steering Committee. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 2017; 3 (03) 192-197
    CrossrefPubMedGoogle Scholar
  • 10 Lyon AR, López-Fernández T, Couch LS. et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 2022; 23 (10) e333-e465
    CrossrefPubMedGoogle Scholar
  • 11 Santoro C, Capone V, Canonico ME. et al. Single, dual, and triple antithrombotic therapy in cancer patients with coronary artery disease: searching for evidence and personalized approaches. Semin Thromb Hemost 2021; 47 (08) 950-961
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69 (01) 7-34
    CrossrefPubMedGoogle Scholar
  • 13 Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the Surveillance, Epidemiology, and End Results Program. JAMA Oncol 2018; 4 (06) 832-836
    CrossrefPubMedGoogle Scholar
  • 14 Wang L, Wang F, Chen L, Geng Y, Yu S, Chen Z. Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study. Eur Heart J 2021; 42 (01) 101-109
    CrossrefPubMedGoogle Scholar
  • 15 Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. J Natl Cancer Inst 1993; 85 (12) 979-987
    CrossrefPubMedGoogle Scholar
  • 16 Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-220
    CrossrefPubMedGoogle Scholar
  • 17 Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63 (10) 945-953
    CrossrefPubMedGoogle Scholar
  • 18 Fradley MG, Ellenberg K, Alomar M. et al. Patterns of anticoagulation use in patients with cancer with atrial fibrillation and/or atrial flutter. JACC Cardiooncol 2020; 2 (05) 747-754
    CrossrefPubMedGoogle Scholar
  • 19 Chen ST, Hellkamp AS, Becker RC. et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes 2019; 5 (02) 145-152
    CrossrefPubMedGoogle Scholar
  • 20 Chu G, Versteeg HH, Verschoor AJ. et al. Atrial fibrillation and cancer - an unexplored field in cardiovascular oncology. Blood Rev 2019; 35: 59-67
    CrossrefPubMedGoogle Scholar
  • 21 Keramida K, Filippatos G, Farmakis D. Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. Eur Heart J Cardiovasc Pharmacother 2021; 7 (04) 321-323
    CrossrefPubMedGoogle Scholar
  • 22 Menichelli D, Vicario T, Ameri P. et al. Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment. Prog Cardiovasc Dis 2021; 66: 28-36
    CrossrefPubMedGoogle Scholar
  • 23 Jakobsen CB, Lamberts M, Carlson N. et al. Incidence of atrial fibrillation in different major cancer subtypes: a nationwide population-based 12 year follow up study. BMC Cancer 2019; 19 (01) 1105
    CrossrefPubMedGoogle Scholar
  • 24 Yun JP, Choi EK, Han KD. et al. Risk of atrial fibrillation according to cancer type: a nationwide population-based study. JACC Cardiooncol 2021; 3 (02) 221-232
    CrossrefPubMedGoogle Scholar
  • 25 Rinde LB, Småbrekke B, Hald EM. et al. Myocardial infarction and future risk of cancer in the general population-the Tromsø study. Eur J Epidemiol 2017; 32 (03) 193-201
    CrossrefPubMedGoogle Scholar
  • 26 O'Neal WT, Claxton JS, Sandesara PB. et al. Provider specialty, anticoagulation, and stroke risk in patients with atrial fibrillation and cancer. J Am Coll Cardiol 2018; 72 (16) 1913-1922
    CrossrefPubMedGoogle Scholar
  • 27 Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol 2010; 30 (03) 311-319
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Shah S, Norby FL, Datta YH. et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv 2018; 2 (03) 200-209
    CrossrefPubMedGoogle Scholar
  • 29 Atterman A, Friberg L, Asplund K, Engdahl J. Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. Europace 2020; 22 (01) 58-65
    CrossrefPubMedGoogle Scholar
  • 30 Pastori D, Marang A, Bisson A. et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer 2021; 127 (12) 2122-2129
    CrossrefPubMedGoogle Scholar
  • 31 Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009; 119 (01) 1-16
    CrossrefPubMedGoogle Scholar
  • 32 Khorana AA, Noble S, Lee AYY. et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (09) 1891-1894
    CrossrefPubMedGoogle Scholar
  • 33 Falanga A, Leader A, Ambaglio C. et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022; 6 (08) e750
    CrossrefPubMedGoogle Scholar
  • 34 Benlachgar N, Doghmi K, Masrar A, Mahtat EM, Harmouche H, Tazi Mezalek Z. Immature platelets: a review of the available evidence. Thromb Res 2020; 195: 43-50
    CrossrefPubMedGoogle Scholar
  • 35 Adelborg K, Kristensen NR, Nørgaard M. et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. J Thromb Haemost 2019; 17 (06) 912-924
    CrossrefPubMedGoogle Scholar
  • 36 Hakim DA, Dangas GD, Caixeta A. et al. Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Am Heart J 2011; 161 (02) 391-396
    CrossrefPubMedGoogle Scholar
  • 37 Kopolovic I, Lee AY, Wu C. Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study. Ann Hematol 2015; 94 (02) 329-336
    CrossrefPubMedGoogle Scholar
  • 38 Kilpatrick K, Shaw JL, Jaramillo R. et al. Occurrence and management of thrombocytopenia in metastatic colorectal cancer patients receiving chemotherapy: secondary analysis of data from prospective clinical trials. Clin Colorectal Cancer 2021; 20 (02) 170-176
    CrossrefPubMedGoogle Scholar
  • 39 Shaw JL, Nielson CM, Park JK, Marongiu A, Soff GA. The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies. Eur J Haematol 2021; 106 (05) 662-672
    CrossrefPubMedGoogle Scholar
  • 40 Barcellini W, Giannotta JA, Fattizzo B. Autoimmune complications in hematologic neoplasms. Cancers (Basel) 2021; 13 (07) 1532
    CrossrefPubMedGoogle Scholar
  • 41 Xie W, Hu N, Cao L. Immune thrombocytopenia induced by immune checkpoint inhibitors in lung cancer: case report and literature review. Front Immunol 2021; 12: 790051
    CrossrefPubMedGoogle Scholar
  • 42 He MM, Lo CH, Wang K. et al. Immune-mediated diseases associated with cancer risks. JAMA Oncol 2022; 8 (02) 209-219
    CrossrefPubMedGoogle Scholar
  • 43 Chandan JS, Thomas T, Lee S. et al. The association between idiopathic thrombocytopenic purpura and cardiovascular disease: a retrospective cohort study. J Thromb Haemost 2018; 16 (03) 474-480
    CrossrefPubMedGoogle Scholar
  • 44 Melloni C, Dunning A, Granger CB. et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 2017; 130 (12) 1440-1448.e1
    CrossrefPubMedGoogle Scholar
  • 45 Stanger L, Yamaguchi A, Holinstat M. Antiplatelet strategies: past, present, and future. J Thromb Haemost 2023; 21 (12) 3317-3328
    CrossrefPubMedGoogle Scholar
  • 46 Hsu C, Patell R, Zwicker JI. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv 2023; 7 (17) 4721-4727
    CrossrefPubMedGoogle Scholar
  • 47 Patel HK, Khorana AA. Anticoagulation in cancer patients: a summary of pitfalls to avoid. Curr Oncol Rep 2019; 21 (02) 18
    CrossrefPubMedGoogle Scholar
  • 48 Wang T, Liu X, Zhu Y. et al. Antithrombotic strategy in cancer patients comorbid with acute coronary syndrome and atrial fibrillation. Front Cardiovasc Med 2023; 10: 1325488
    CrossrefPubMedGoogle Scholar
  • 49 Font J, Milliez P, Ouazar AB, Klok FA, Alexandre J. Atrial fibrillation, cancer and anticancer drugs. Arch Cardiovasc Dis 2023; 116 (04) 219-226
    CrossrefPubMedGoogle Scholar
  • 50 Kirschner M, do Ó Hartmann N, Parmentier S. et al. Primary thromboprophylaxis in patients with malignancies: daily practice recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO), the Society of Thrombosis and Hemostasis Research (GTH), and the Austrian Society of Hematology and Oncology (ÖGHO). Cancers (Basel) 2021; 13 (12) 2905
    CrossrefPubMedGoogle Scholar
  • 51 Steffel J, Collins R, Antz M. et al; External Reviewers. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23 (10) 1612-1676
    CrossrefPubMedGoogle Scholar
  • 52 CNSPVF. Atlas de la fin de vie. Accessed June 7, 2024 at: https://wwwtheragorafr/pdfs/Atlas_Soins_Plliatifs_Fin_de_Vie_en_Francepdf 2018
    PubMedGoogle Scholar
  • 53 Sheard L, Prout H, Dowding D. et al. The ethical decisions UK doctors make regarding advanced cancer patients at the end of life – the perceived (in) appropriateness of anticoagulation for venous thromboembolism: a qualitative study. BMC Med Ethics 2012; 13: 22
    CrossrefPubMedGoogle Scholar
  • 54 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020; 38 (05) 496-520
    CrossrefPubMedGoogle Scholar
  • 55 Falanga A, Ay C, Di Nisio M. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol 2023; 34 (05) 452-467
    CrossrefPubMedGoogle Scholar
  • 56 Bauersachs RM, Herold J. Oral anticoagulation in the elderly and frail. Hamostaseologie 2020; 40 (01) 74-83
    Article in Thieme ConnectPubMedGoogle Scholar
  • 57 Sabatino J, De Rosa S, Polimeni A, Sorrentino S, Indolfi C. Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis. JACC Cardiooncol 2020; 2 (03) 428-440
    CrossrefPubMedGoogle Scholar
  • 58 Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ. Association for Palliative Medicine for Great Britain and Ireland. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (06) 577-584
    CrossrefPubMedGoogle Scholar
  • 59 Raby J, Bradley V, Sabharwal N. Anticoagulation for patients with mechanical heart valves at the end of life: understanding clinician attitudes and improving decision making. BMC Palliat Care 2021; 20 (01) 113
    CrossrefPubMedGoogle Scholar
  • 60 Ouellet GM, Fried TR, Gilstrap LG. et al. Anticoagulant use for atrial fibrillation among persons with advanced dementia at the end of life. JAMA Intern Med 2021; 181 (08) 1121-1123
    CrossrefPubMedGoogle Scholar
  • 61 Hedman C, Frisk G, Björkhem-Bergman L. Deprescribing in palliative cancer care. Life (Basel) 2022; 12 (05) 613
    PubMedGoogle Scholar
  • 62 Chin-Yee N, Tanuseputro P, Carrier M, Noble S. Thromboembolic disease in palliative and end-of-life care: a narrative review. Thromb Res 2019; 175: 84-89
    CrossrefPubMedGoogle Scholar
  • 63 Ahuja T, Manmadhan A, Berger JS. To deprescribe or not to deprescribe aspirin - a clear indication is the challenge. JAMA Intern Med 2021; 181 (11) 1540-1541
    CrossrefPubMedGoogle Scholar
  • 64 Bourgeois H, Grudé F, Solal-Céligny P. et al. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Ann Oncol 2017; 28 (07) 1612-1617
    CrossrefPubMedGoogle Scholar
  • 65 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395 (10226): 785-794
    CrossrefPubMedGoogle Scholar
  • 66 Meijers WC, Maglione M, Bakker SJL. et al. Heart failure stimulates tumor growth by circulating factors. Circulation 2018; 138 (07) 678-691
    CrossrefPubMedGoogle Scholar
  • 67 Madnick DL, Fradley MG. Atrial fibrillation and cancer patients: mechanisms and management. Curr Cardiol Rep 2022; 24 (10) 1517-1527
    CrossrefPubMedGoogle Scholar
  • 68 Eschenhagen T, Force T, Ewer MS. et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13 (01) 1-10
    CrossrefPubMedGoogle Scholar
  • 69 Ghadri JR, Wittstein IS, Prasad A. et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): diagnostic workup, outcome, and management. Eur Heart J 2018; 39 (22) 2047-2062
    CrossrefPubMedGoogle Scholar
  • 70 Ghadri JR, Wittstein IS, Prasad A. et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology. Eur Heart J 2018; 39 (22) 2032-2046
    CrossrefPubMedGoogle Scholar
  • 71 Demers M, Krause DS, Schatzberg D. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A 2012; 109 (32) 13076-13081
    CrossrefPubMedGoogle Scholar
  • 72 Mrotzek SM, Lena A, Hadzibegovic S. et al. Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol 2021; 110 (02) 200-210
    CrossrefPubMedGoogle Scholar
  • 73 Nykl R, Fischer O, Vykoupil K, Taborsky M. A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI) - systemic inflammatory response syndrome after use of pembrolizumab. Arch Med Sci Atheroscler Dis 2017; 2: e100-e102
    CrossrefPubMedGoogle Scholar
  • 74 Ferreira M, Pichon E, Carmier D. et al. Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries. Target Oncol 2018; 13 (04) 509-515
    CrossrefPubMedGoogle Scholar
  • 75 Navi BB, Reiner AS, Kamel H. et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019; 133 (08) 781-789
    CrossrefPubMedGoogle Scholar
  • 76 Anker MS, Sanz AP, Zamorano JL. et al. Advanced cancer is also a heart failure syndrome: a hypothesis. J Cachexia Sarcopenia Muscle 2021; 12 (03) 533-537
    CrossrefPubMedGoogle Scholar
  • 77 Zaorsky NG, Churilla TM, Egleston BL. et al. Causes of death among cancer patients. Ann Oncol 2017; 28 (02) 400-407
    CrossrefPubMedGoogle Scholar
  • 78 Dolly A, Dumas JF, Servais S. Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?. J Cachexia Sarcopenia Muscle 2020; 11 (06) 1413-1428
    CrossrefPubMedGoogle Scholar
  • 79 Tian M, Nishijima Y, Asp ML, Stout MB, Reiser PJ, Belury MA. Cardiac alterations in cancer-induced cachexia in mice. Int J Oncol 2010; 37 (02) 347-353
    PubMedGoogle Scholar
  • 80 Springer J, Tschirner A, Haghikia A. et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 2014; 35 (14) 932-941
    CrossrefPubMedGoogle Scholar
  • 81 Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. ESC Heart Fail 2017; 4 (04) 458-467
    CrossrefPubMedGoogle Scholar
  • 82 Kazemi-Bajestani SMR, Becher H, Butts C. et al. Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. J Cachexia Sarcopenia Muscle 2019; 10 (05) 1070-1082
    CrossrefPubMedGoogle Scholar
  • 83 Anker MS, von Haehling S, Coats AJS. et al. Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. Eur J Heart Fail 2021; 23 (01) 145-153
    CrossrefPubMedGoogle Scholar
  • 84 Cheung CC, Nattel S, Macle L, Andrade JG. Management of atrial fibrillation in 2021: an updated comparison of the current CCS/CHRS, ESC, and AHA/ACC/HRS guidelines. Can J Cardiol 2021; 37 (10) 1607-1618
    CrossrefPubMedGoogle Scholar
  • 85 D'Souza M, Carlson N, Fosbøl E. et al. CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol 2018; 25 (06) 651-658
    CrossrefPubMedGoogle Scholar
  • 86 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137 (02) 263-272
    CrossrefPubMedGoogle Scholar
  • 87 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    CrossrefPubMedGoogle Scholar
  • 88 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74 (01) 104-132
    CrossrefPubMedGoogle Scholar
  • 89 Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol 2017; 120 (12) 2182-2186
    CrossrefPubMedGoogle Scholar
  • 90 Hu YF, Liu CJ, Chang PM. et al. Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 2013; 165 (02) 355-357
    CrossrefPubMedGoogle Scholar
  • 91 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138 (05) 1093-1100
    CrossrefPubMedGoogle Scholar
  • 92 Gao X, Cai X, Yang Y, Zhou Y, Zhu W. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021; 8: 757087
    CrossrefPubMedGoogle Scholar
  • 93 Raposeiras Roubín S, Abu Assi E, Muñoz Pousa I. et al. Incidence and predictors of bleeding in patients with cancer and atrial fibrillation. Am J Cardiol 2022; 167: 139-146
    CrossrefPubMedGoogle Scholar
  • 94 Tafur AJ, McBane II R, Wysokinski WE. et al. Predictors of major bleeding in peri-procedural anticoagulation management. J Thromb Haemost 2012; 10 (02) 261-267
    CrossrefPubMedGoogle Scholar
  • 95 Fanola CL, Ruff CT, Murphy SA. et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial. J Am Heart Assoc 2018; 7 (16) e008987
    CrossrefPubMedGoogle Scholar
  • 96 Connolly SJ, Ezekowitz MD, Yusuf S. et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361 (12) 1139-1151
    CrossrefPubMedGoogle Scholar
  • 97 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedGoogle Scholar
  • 98 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedGoogle Scholar
  • 99 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
    CrossrefPubMedGoogle Scholar
  • 100 Mariani MV, Magnocavallo M, Straito M. et al. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. J Thromb Thrombolysis 2021; 51 (02) 419-429
    CrossrefPubMedGoogle Scholar
  • 101 Deitelzweig S, Keshishian AV, Zhang Y. et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer. JACC Cardiooncol 2021; 3 (03) 411-424
    CrossrefPubMedGoogle Scholar
  • 102 Farmakis D. Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think. Eur J Prev Cardiol 2021; 28 (06) 608-610
    CrossrefPubMedGoogle Scholar
  • 103 López-Fernández T, Martín-García A, Roldán Rabadán I. et al; Expert reviewers. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol (Engl Ed) 2019; 72 (09) 749-759
    PubMedGoogle Scholar
  • 104 Lee AY, Levine MN, Baker RI. et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 105 Lee AYY, Kamphuisen PW, Meyer G. et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 106 Agnelli G, Becattini C, Meyer G. et al; Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
    CrossrefPubMedGoogle Scholar
  • 107 Raskob GE, van Es N, Verhamme P. et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 108 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 109 Riess H, Beyer-Westendorf J, Pelzer U, Klamroth R, Linnemann B. Cancer-associated venous thromboembolism-diagnostic and therapeutic considerations: an update based on the revised AWMF S2k guideline. Hamostaseologie 2024; 44 (02) 143-149
    Article in Thieme ConnectPubMedGoogle Scholar
  • 110 Linnemann B, Blank W, Doenst T. Diagnostik und Therapie der tiefen Venenthrombose und Lungenembollie - AWMF-S2k-Leitlinie. Stand: 11.01.2023. Verfügbar unter. Accessed June 8, 2024 at: https://register.awmf.org/de/leitlinien/detail/065-002 2023
    PubMedGoogle Scholar
  • 111 Elias A, Morgenstern Y, Braun E, Brenner B, Tzoran I. Direct oral anticoagulants versus enoxaparin in patients with atrial fibrillation and active cancer. Eur J Intern Med 2021; 89: 132-134
    CrossrefPubMedGoogle Scholar
  • 112 Delluc A, Wang TF, Yap ES. et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH. J Thromb Haemost 2019; 17 (08) 1247-1252
    CrossrefPubMedGoogle Scholar
  • 113 Atterman A, Friberg L, Asplund K, Engdahl J. Atrial fibrillation, oral anticoagulants, and concomitant active cancer: benefits and risks. TH Open 2021; 5 (02) e176-e182
    Article in Thieme ConnectPubMedGoogle Scholar
  • 114 Leader A, Hamulyák EN, Carney BJ. et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. Blood Adv 2020; 4 (24) 6291-6297
    CrossrefPubMedGoogle Scholar
  • 115 Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022; 6 (16) 4873-4883
    CrossrefPubMedGoogle Scholar
  • 116 Isogai T, Saad AM, Abushouk AI. et al. Procedural and short-term outcomes of percutaneous left atrial appendage closure in patients with cancer. Am J Cardiol 2021; 141: 154-157
    CrossrefPubMedGoogle Scholar
  • 117 Jones LW, Habel LA, Weltzien E. et al. Exercise and risk of cardiovascular events in women with nonmetastatic breast cancer. J Clin Oncol 2016; 34 (23) 2743-2749
    CrossrefPubMedGoogle Scholar
  • 118 Carlson LE, Watt GP, Tonorezos ES. et al; WECARE Study Collaborative Group. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC Cardiooncol 2021; 3 (03) 381-392
    CrossrefPubMedGoogle Scholar
  • 119 Shrestha S, Bates JE, Liu Q. et al. Radiation therapy related cardiac disease risk in childhood cancer survivors: updated dosimetry analysis from the Childhood Cancer Survivor Study. Radiother Oncol 2021; 163: 199-208
    CrossrefPubMedGoogle Scholar
  • 120 Wang K, Eblan MJ, Deal AM. et al. Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: pooled analysis of dose-escalation trials delivering 70 to 90 Gy. J Clin Oncol 2017; 35 (13) 1387-1394
    CrossrefPubMedGoogle Scholar
  • 121 Bharadwaj A, Potts J, Mohamed MO. et al. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur Heart J 2020; 41 (23) 2183-2193
    CrossrefPubMedGoogle Scholar
  • 122 Iannaccone M, D'Ascenzo F, Vadalà P. et al. Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy. Eur Heart J Acute Cardiovasc Care 2018; 7 (07) 631-638
    CrossrefPubMedGoogle Scholar
  • 123 Park JY, Guo W, Al-Hijji M. et al. Acute coronary syndromes in patients with active hematologic malignancies - incidence, management, and outcomes. Int J Cardiol 2019; 275: 6-12
    CrossrefPubMedGoogle Scholar
  • 124 Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol 2012; 35 (07) 443-450
    CrossrefPubMedGoogle Scholar
  • 125 Potts JE, Iliescu CA, Lopez Mattei JC. et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2019; 40 (22) 1790-1800
    CrossrefPubMedGoogle Scholar
  • 126 Ueki Y, Vögeli B, Karagiannis A. et al. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC Cardiooncol 2019; 1 (02) 145-155
    CrossrefPubMedGoogle Scholar
  • 127 Mohamed MO, Van Spall HGC, Kontopantelis E. et al. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 2021; 10 (08) 829-839
    CrossrefPubMedGoogle Scholar
  • 128 Garatti A, D'Ovidio M, Saitto G. et al. Coronary artery bypass grafting in patients with concomitant solid tumours: early and long-term results. Eur J Cardiothorac Surg 2020; 58 (03) 528-536
    CrossrefPubMedGoogle Scholar
  • 129 Wang FM, Reiter-Brennan C, Dardari Z. et al. Association between coronary artery calcium and cardiovascular disease as a supporting cause in cancer: The CAC consortium. Am J Prev Cardiol 2020; 4: 100119
    CrossrefPubMedGoogle Scholar
  • 130 Lyon AR, López-Fernández T, Couch LS. et al; ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 2022; 43 (41) 4229-4361
    CrossrefPubMedGoogle Scholar
  • 131 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
    CrossrefPubMedGoogle Scholar
  • 132 Marin-Barrera L, Muñoz-Martin AJ, Rios-Herranz E. et al. A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: Quality of Life in Cancer (Qca) Study. Cancers (Basel) 2019; 12 (01) 75
    CrossrefPubMedGoogle Scholar
  • 133 Lyman GH. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117 (07) 1334-1349
    CrossrefPubMedGoogle Scholar
  • 134 Prandoni P, Lensing AW, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 135 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 136 Gregson J, Kaptoge S, Bolton T. et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4 (02) 163-173
    CrossrefPubMedGoogle Scholar
  • 137 Laconi E, Marongiu F, DeGregori J. Cancer as a disease of old age: changing mutational and microenvironmental landscapes. Br J Cancer 2020; 122 (07) 943-952
    CrossrefPubMedGoogle Scholar
  • 138 Di Nisio M, Ferrante N, De Tursi M. et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104 (05) 1049-1054
    PubMedGoogle Scholar
  • 139 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedGoogle Scholar
  • 140 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
    CrossrefPubMedGoogle Scholar
  • 141 Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014; 134 (06) 1214-1219
    CrossrefPubMedGoogle Scholar
  • 142 van der Wall SJ, Klok FA, den Exter PL. et al. Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. J Thromb Haemost 2017; 15 (01) 74-79
    CrossrefPubMedGoogle Scholar
  • 143 Chapelle C, Ollier E, Girard P. et al. An epidemic of redundant meta-analyses. J Thromb Haemost 2021; 19 (05) 1299-1306
    CrossrefPubMedGoogle Scholar
  • 144 McBane II RD, Wysokinski WE, Le-Rademacher JG. et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020; 18 (02) 411-421
    CrossrefPubMedGoogle Scholar
  • 145 Planquette B, Bertoletti L, Charles-Nelson A. et al; CASTA DIVA Trial Investigators. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2022; 161 (03) 781-790
    CrossrefPubMedGoogle Scholar
  • 146 Schrag D, Uno H, Rosovsky R. et al; CANVAS Investigators. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 2023; 329 (22) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 147 Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: updated systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020; 4 (04) 550-561
    CrossrefPubMedGoogle Scholar
  • 148 Farge D, Frere C, Connors JM. et al; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019; 20 (10) e566-e581
    CrossrefPubMedGoogle Scholar
  • 149 National Comprehensive Cancer Network. NCCN guideline on cancer-associated venous thromboembolic disease. Version 1.2021. Accessed June 8, 2024 at: https://www.nccn.org/professionals/physician.gls/pdf/vte.pdf
    PubMedGoogle Scholar
  • 150 Lyman GH, Carrier M, Ay C. et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021; 5 (04) 927-974
    CrossrefPubMedGoogle Scholar
  • 151 Stevens SM, Woller SC, Baumann Kreuziger L. et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160 (06) 2247-2259
    CrossrefPubMedGoogle Scholar
  • 152 Carrier M, Blais N, Crowther M. et al. Treatment algorithm in cancer-associated thrombosis: updated Canadian Expert Consensus. Curr Oncol 2021; 28 (06) 5434-5451
    CrossrefPubMedGoogle Scholar
  • 153 McBane II RD, Loprinzi CL, Ashrani A. et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol 2020; 104 (02) 88-96
    CrossrefPubMedGoogle Scholar
  • 154 Mahe I, Agnelli G, Bamias A, Ay C, Becattini C, Carrier M. et al. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thromb Haemost 2022; 122 (04) 646-56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 155 McBane II RD, Loprinzi CL, Ashrani A. et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: EVE trial. ISTH 2023 Congress June 24–28, 2023. Abstract LB 021. 2023
    PubMedGoogle Scholar
  • 156 Kumbhani DJ, Cannon CP, Beavers CJ. et al. 2020 ACC Expert Consensus Decision Pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021; 77 (05) 629-658
    CrossrefPubMedGoogle Scholar
  • 157 Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 2015; 100 (11) 1486-1492
    CrossrefPubMedGoogle Scholar
  • 158 Hunault-Berger M, Chevallier P, Delain M. et al; GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang). Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study. Haematologica 2008; 93 (10) 1488-1494
    CrossrefPubMedGoogle Scholar
  • 159 Kwaan HC. Double hazard of thrombophilia and bleeding in leukemia. Hematology (Am Soc Hematol Educ Program) 2007; 151-157
    CrossrefPubMedGoogle Scholar
  • 160 Shatzel JJ, Olson SR, Tao DL, McCarty OJT, Danilov AV, DeLoughery TG. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies. J Thromb Haemost 2017; 15 (05) 835-847
    CrossrefPubMedGoogle Scholar
  • 161 Boriani G, Corradini P, Cuneo A. et al. Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding. Hematol Oncol 2018; 36 (04) 624-632
    CrossrefPubMedGoogle Scholar
  • 162 Kuter DJ, Efraim M, Mayer J. et al. Rilzabrutinib, an oral BTK inhibitor, in immune thrombocytopenia. N Engl J Med 2022; 386 (15) 1421-1431
    CrossrefPubMedGoogle Scholar
  • 163 Peixoto de Miranda EJF, Takahashi T, Iwamoto F. et al. Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms. Clin Appl Thromb Hemost 2020; 26: 1076029620936325
    CrossrefPubMedGoogle Scholar
  • 164 Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol 2018; 132: 169-179
    CrossrefPubMedGoogle Scholar
  • 165 Short NJ, Connors JM. New oral anticoagulants and the cancer patient. Oncologist 2014; 19 (01) 82-93
    CrossrefPubMedGoogle Scholar
  • 166 Parasrampuria DA, Mendell J, Shi M, Matsushima N, Zahir H, Truitt K. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine. Br J Clin Pharmacol 2016; 82 (06) 1591-1600
    CrossrefPubMedGoogle Scholar
  • 167 Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (08) 1296-1310
    CrossrefPubMedGoogle Scholar
  • 168 Patmore S, Dhami SPS, O'Sullivan JM. Von Willebrand factor and cancer; metastasis and coagulopathies. J Thromb Haemost 2020; 18 (10) 2444-2456
    CrossrefPubMedGoogle Scholar
  • 169 Jones E, Dillon B, Swan D, Thachil J. Practical management of the haemorrhagic complications of myeloproliferative neoplasms. Br J Haematol 2022; 199 (03) 313-321
    CrossrefPubMedGoogle Scholar
  • 170 Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther 2009; 31 (Pt 2): 2416-2432
    CrossrefPubMedGoogle Scholar
  • 171 Ten Berg MJ, van den Bemt PM, Shantakumar S. et al. Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study. Drug Saf 2011; 34 (12) 1151-1160
    CrossrefPubMedGoogle Scholar
  • 172 Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Hematology (Am Soc Hematol Educ Program) 2019; 2019 (01) 71-79
    CrossrefPubMedGoogle Scholar
  • 173 Samuelson Bannow BT, Lee A, Khorana AA. et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16 (06) 1246-1249
    CrossrefPubMedGoogle Scholar
  • 174 Samuelson Bannow BR, Lee AYY, Khorana AA. et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review. Res Pract Thromb Haemost 2018; 2 (04) 664-669
    CrossrefPubMedGoogle Scholar
  • 175 Leader A, Gurevich-Shapiro A, Spectre G. Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia. Thromb Res 2020; 191 (Suppl. 01) S68-S73
    CrossrefPubMedGoogle Scholar
  • 176 Wang CL, Wu VC, Lee CH. et al. Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia. J Thromb Thrombolysis 2019; 47 (04) 512-519
    CrossrefPubMedGoogle Scholar
  • 177 Janion-Sadowska A, Papuga-Szela E, Łukaszuk R, Chrapek M, Undas A. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and thrombocytopenia. J Cardiovasc Pharmacol 2018; 72 (03) 153-160
    CrossrefPubMedGoogle Scholar
  • 178 Chehab O, Abdallah N, Kanj A. et al. Impact of immune thrombocytopenic purpura on clinical outcomes in patients with acute myocardial infarction. Clin Cardiol 2020; 43 (01) 50-59
    CrossrefPubMedGoogle Scholar
  • 179 Matzdorff A, Beer JH. Immune thrombocytopenia patients requiring anticoagulation – maneuvering between Scylla and Charybdis. Semin Hematol 2013; 50 (Suppl. 01) S83-S88
    CrossrefPubMedGoogle Scholar
  • 180 McCarthy CP, Steg G, Bhatt DL. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. Eur Heart J 2017; 38 (47) 3488-3492
    CrossrefPubMedGoogle Scholar
  • 181 Pishko AM, Misgav M, Cuker A. et al. Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists. J Thromb Thrombolysis 2018; 46 (01) 24-30
    CrossrefPubMedGoogle Scholar
  • 182 Samuelson BT, Gernsheimer T, Estey E, Garcia DA. Variability in management of hematologic malignancy patients with venous thromboembolism and chemotherapy-induced thrombocytopenia. Thromb Res 2016; 141: 104-105
    CrossrefPubMedGoogle Scholar
  • 183 Carrier M, Khorana AA, Zwicker J, Noble S, Lee AY. Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. J Thromb Haemost 2013; 11 (09) 1760-1765
    CrossrefPubMedGoogle Scholar
  • 184 Patel SJ, Ajebo G, Kota V, Guddati AK. Outcomes of hospitalized patients with myocardial infarction and immune thrombocytopenic purpura: a cross sectional study over 15 years. Am J Blood Res 2020; 10 (05) 210-216
    PubMedGoogle Scholar
  • 185 Lee CH, Kim U. Revascularization for patients with idiopathic thrombocytopenic purpura and coronary artery disease. Korean Circ J 2014; 44 (04) 264-267
    CrossrefPubMedGoogle Scholar
  • 186 Russo A, Cannizzo M, Ghetti G. et al. Idiopathic thrombocytopenic purpura and coronary artery disease: comparison between coronary artery bypass grafting and percutaneous coronary intervention. Interact Cardiovasc Thorac Surg 2011; 13 (02) 153-157
    CrossrefPubMedGoogle Scholar
  • 187 Al-Lawati K, Osheiba M, Lester W, Khan SQ. Management of acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura, the value of optical coherence tomography: a case report. Eur Heart J Case Rep 2020; 4 (06) 1-5
    CrossrefPubMedGoogle Scholar
  • 188 Bhatt DL, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140 (01) 67-73
    CrossrefPubMedGoogle Scholar
  • 189 Watanabe H, Domei T, Morimoto T. et al; STOPDAPT-2 Investigators. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019; 321 (24) 2414-2427
    CrossrefPubMedGoogle Scholar
  • 190 Goel R, Chopra S, Tobian AAR. et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion 2019; 59 (01) 169-176
    CrossrefPubMedGoogle Scholar
  • 191 Ayoub K, Marji M, Ogunbayo G. et al. Impact of chronic thrombocytopenia on in-hospital outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv 2018; 11 (18) 1862-1868
    CrossrefPubMedGoogle Scholar
  • 192 Fuchi T, Kondo T, Sase K, Takahashi M. Primary percutaneous transluminal coronary angioplasty performed for acute myocardial infarction in a patient with idiopathic thrombocytopenic purpura. Jpn Circ J 1999; 63 (02) 133-136
    CrossrefPubMedGoogle Scholar
  • 193 Raphael CE, Spoon DB, Bell MR. et al. Effect of preprocedural thrombocytopenia on prognosis after percutaneous coronary intervention. Mayo Clin Proc 2016; 91 (08) 1035-1044
    CrossrefPubMedGoogle Scholar
  • 194 Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med 2013; 173 (02) 132-139
    CrossrefPubMedGoogle Scholar
  • 195 Neunert C, Terrell DR, Arnold DM. et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3 (23) 3829-3866
    CrossrefPubMedGoogle Scholar
  • 196 Arber DA, Orazi A, Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127 (20) 2391-2405
    CrossrefPubMedGoogle Scholar
  • 197 Barbui T, Carobbio A, Cervantes F. et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010; 115 (04) 778-782
    CrossrefPubMedGoogle Scholar
  • 198 Barbui T, Finazzi G, Carobbio A. et al. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120 (26) 5128-5133 , quiz 5252
    CrossrefPubMedGoogle Scholar
  • 199 Carobbio A, Thiele J, Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood 2011; 117 (22) 5857-5859
    CrossrefPubMedGoogle Scholar
  • 200 Barbui T, Carobbio A, Rumi E. et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014; 124 (19) 3021-3023
    CrossrefPubMedGoogle Scholar
  • 201 Patrono C, Rocca B, De Stefano V. Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. Blood 2013; 121 (10) 1701-1711
    CrossrefPubMedGoogle Scholar
  • 202 Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013; 122 (13) 2176-2184
    CrossrefPubMedGoogle Scholar
  • 203 Barbui T, Tefferi A, Vannucchi AM. et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 2018; 32 (05) 1057-1069
    CrossrefPubMedGoogle Scholar
  • 204 Landolfi R, Marchioli R, Kutti J. et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350 (02) 114-124
    CrossrefPubMedGoogle Scholar
  • 205 De Stefano V, Carobbio A, Di Lazzaro V. et al. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer J 2018; 8 (03) 25
    CrossrefPubMedGoogle Scholar
  • 206 Hernández-Boluda JC, Arellano-Rodrigo E, Cervantes F. et al; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 2015; 94 (06) 911-918
    CrossrefPubMedGoogle Scholar
  • 207 Ianotto JC, Couturier MA, Galinat H. et al. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 2017; 106 (04) 517-521
    CrossrefPubMedGoogle Scholar
  • 208 Fedorov K, Goel S, Kushnir M, Billett HH. Direct oral anticoagulants for prevention of recurrent thrombosis in myeloproliferative neoplasms. Blood 2019; 134 (Suppl. 01) 4193
    CrossrefPubMedGoogle Scholar
  • 209 Huenerbein K, Sadjadian P, Becker T. et al. Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Ann Hematol 2021; 100 (08) 2015-2022
    CrossrefPubMedGoogle Scholar
  • 210 Barbui T, De Stefano V, Carobbio A. et al. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia 2021; 35 (10) 2989-2993
    CrossrefPubMedGoogle Scholar
  • 211 Zwicker JI, Paranagama D, Lessen DS, Colucci PM, Grunwald MR. Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. Haematologica 2022; 107 (05) 1106-1110
    CrossrefPubMedGoogle Scholar
  • 212 Kreher S, Ochsenreither S, Trappe RU. et al; Haemostasis Working Party of the German Society of Hematology and Oncology, Austrian Society of Hematology and Oncology, Society of Thrombosis and Haemostasis Research. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol 2014; 93 (12) 1953-1963
    CrossrefPubMedGoogle Scholar
  • 213 Appelmann I, Kreher S, Parmentier S. et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol 2016; 95 (05) 707-718
    CrossrefPubMedGoogle Scholar
  • 214 Paciullo F, Bury L, Noris P. et al. Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica 2020; 105 (07) 1948-1956
    CrossrefPubMedGoogle Scholar
  • 215 Rodeghiero F, Tosetto A, Abshire T. et al; ISTH/SSC Joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8 (09) 2063-2065
    CrossrefPubMedGoogle Scholar
  • 216 Gresele P, Orsini S, Noris P. et al; BAT-VAL Study Investigators. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: a communication from the Platelet Physiology SSC. J Thromb Haemost 2020; 18 (03) 732-739
    CrossrefPubMedGoogle Scholar
  • 217 Balitsky AK, Kelton JG, Arnold DM. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. Blood 2018; 132 (25) 2684-2686
    CrossrefPubMedGoogle Scholar
  • 218 Sawant AC, Kumar A, Mccray W. et al. Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national Veterans Affairs database study. J Geriatr Cardiol 2019; 16 (09) 706-709
    PubMedGoogle Scholar
  • 219 Boriani G, Lee G, Parrini I. et al; Council of Cardio-Oncology of the European Society of Cardiology. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol 2021; 28 (06) 611-621
    CrossrefPubMedGoogle Scholar
  • 220 Sebuhyan M, Crichi B, Deville L. et al. Patient education program at the forefront of cancer-associated thrombosis care. J Med Vasc 2021; 46 (5-6): 215-223
    PubMedGoogle Scholar